PFE
New chapter, same bladder-cancer playbook
Pfizer and Astellas just got a Priority Review from the FDA for their supplemental BLA for PADCEV plus Keytruda in perioperative muscle-invasive bladder cancer. Translation: the agency is moving this one to the front of the line instead of making it wait in the DMV of drug approvals.
Why investors should care
This isn’t just paperwork. The filing leans on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial, which is exactly the kind of clinical fuel that can turn a combo therapy from “interesting” into “potential franchise.”
If approved, the regimen would be the first and only perioperative treatment for MIBC regardless of cisplatin eligibility. That matters because “first and only” is pharma’s favorite phrase after “blockbuster.” It can mean more durable sales, a stronger moat, and one less reason for doctors to shop around.
The bigger picture
Pfizer already has this regimen approved for cisplatin-ineligible patients, so this move is more like widening the funnel than starting from scratch. But widening the label can still widen the revenue lane — especially if the FDA ultimately says yes.
Big picture: in pharma, a Priority Review isn’t a victory lap. But it is the FDA basically saying, “We’ll see you sooner,” and that’s a lot better than being stuck in the back of the line.